Pharmaceutical Venture Capital & Private Equity Firms Directory 2023: Direct Access to Over 500 Firms and Thousands of Partners – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “The Directory of Pharmaceutical Venture Capital & Private Equity Firms 2023” directory has been added to ResearchAndMarkets.com’s offering.
This useful resource brings together both venture capital and private equity investors involved in pharmaceuticals, biotechnology and medical devices.
This edition has been extensively updated, offering valuable, current, and detailed information to individuals, entrepreneurs, and businesses worldwide. The new edition is the most current, comprehensive picture of this dynamic industry to date. All company profiles include specifics a data that create detailed picture of the firm and its investment parameters.
This database offers direct access to over 500 firms and thousands of partners with detailed contact information and extensive data on investment and funds. The Directory provided accurate information on:
Firm Name, Address, Phone & Fax Numbers
Managing Partners with their Degrees, Directorships & Professional Background
E-Mail and Website Addresses
Average & Minimum Investments
Investment Criteria/Stage Preferences
Industry Preferences & Geographic Preferences
Categories of industries included in this Directory are:
Research & Development
This Directory will enable you to:
Find Firms that are specifically interested in their industry group.
Search for Firms that match the investment level they need. From $200,000 to $50 million, you’ll be able to generate a list to match your requirements.
Find which Venture Capital Firms have funded specific companies.
For more information about this directory visit https://www.researchandmarkets.com/r/37l21k
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.